Shares of Medpace Holdings Inc. (MEDP) are down 16% from their 52-week high of $459.77, recorded last month, and trade around $385.
Medpace is a global full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com